Geneva, Switzerland – November 18, 2016 – Today, the Sabin Vaccine Institute (Sabin) begins its formal partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), as a member of CEPI’s Joint Coordination Group (JCG). Global health leaders gather in Geneva, Switzerland for the first meeting of the JCG.
CEPI is a global non-profit, public-private partnership that is facilitating vaccine development for diseases of epidemic potential and was founded by the Governments of Norway and India, the Bill and Melinda Gates Foundation, the Wellcome Trust and the World Economic Forum. Recent Ebola and Zika virus outbreaks illustrate that a concerted effort by dedicated and coordinated partners is required to prevent infectious disease outbreaks from becoming humanitarian crises. CEPI’s partnership model is designed to ensure that vaccine candidates move through trials in a timely manner to prevent and contain epidemics before they begin.
Sabin joins CEPI’s JCG as a committed leader in preventing and alleviating human suffering by accelerating access to and uptake of existing vaccines, while researching and developing new vaccines to prevent infectious and neglected diseases. Sabin is a trusted and effective partner in the vaccine policy and advocacy space with a history of bringing together all interests – policymakers, private companies, governments, researchers and advocates – with the common goal of advancing vaccine-preventable disease health. For over a decade, Sabin has also worked to develop new, cost-effective vaccines that often would have limited commercial market. Among its research and development efforts, Sabin researchers are currently investigating vaccine candidates for the deadly infectious diseases Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). As a member of the JCG, Sabin will work with partner organizations to advise on strategic direction and policy oversight.
“I applaud CEPI’s multifaceted approach to vaccine preparedness, which recognizes the broader needs of the vaccine development pathway,” said Amy Finan, chief executive officer of the Sabin Vaccine Institute. “CEPI’s work will not only build the R&D pipeline, but also strengthen market predictability and accelerate outbreak response. It’s an honor for Sabin to join CEPI’s Joint Coordination Group today, and we look forward to strengthening vaccine preparedness with the goal of preventing future global health crisis.”
Today’s inaugural JCG meeting will bring together more than 75 representatives from a variety of public and private organizations to discuss the role of CEPI in the end-to-end spectrum of vaccine preparedness. The JCG is chaired by former FDA Commissioner Margaret Hamburg. Topics of discussion will include methods to secure preclinical pipelines for emerging infectious disease vaccines and aligning investments for clinical development.
About The Sabin Vaccine Institute
The Sabin Vaccine Institute (Sabin) is a non-profit, 501(c)(3) organization dedicated to reducing needless human suffering from vaccine-preventable and neglected tropical diseases (NTDs) worldwide. Sabin develops new vaccines, advocates for increased use of existing vaccines and promotes expanded access to affordable medical treatments in collaboration with governments, academic institutions, scientists, medical professionals and non-profit organizations. For more information, please visit www.sabin.org.
Sabin’s research and development of new vaccines is conducted through the Sabin Vaccine Institute Product Development Partnership, based at the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development in partnership with Baylor College of Medicine. Sabin works with leading private, academic and public institutions around the world to develop and test safe, effective and low-cost vaccines that benefit the world’s poorest communities. A complete overview of ongoing projects and partners is available at www.sabin.org/pdp.